This post was originally published on this site Aravive is recruiting participants for a Phase 1/2 clinical trial assessing a combination of its experimental treatment AVB-500 plus the immune checkpoint inhibitor Imfinzi (durvalumab) in women with platinum-resistant epithelial ovarian cancer. The trial (NCT04019288) is ongoing at the MD Anderson Cancer Center, in Texas, and is…
Conditions
Conditions
Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows
This post was originally published on this site Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in DNA repair genes, particularly the BRCA1 and BRCA2 genes, according to data from a Phase 2 study. The study’s final data, “Olaparib in patients…
Caregivers in Search of Christmas Spirit
This post was originally published on this site “I wish we could put up some of the Christmas spirit in jars and open a jar of it every month.” —Harlan Miller For many people, Christmas is the most wonderful time of the year. The hustle and bustle of shopping for the perfect present, the ringing…
FDA Grants Breakthrough Therapy Status to Tucatinib for Advanced HER2-Positive Breast Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Seattle Genetics’ tucatinib, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with locally advanced inoperable or metastatic HER2-positive breast cancer. The designation, which also includes those with brain metastases, is…
Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible for stem cell transplants, compared with Revlimid and dexamethasone alone, results from a Phase 3 trial show. The combination did help patients live 13.5 months longer…
China Reviewing Zejula as First-line Therapy for Ovarian Cancer
The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding to platinum-based chemotherapy, the company announced. The supplemental New Drug Application (sNDA), submitted to the China National Medical Products Administration (NMPA), is for women with advanced epithelial…
Taking Dantrium via Nose More Effective than by Mouth, Lowers Dose, Study Suggests
Giving Dantrium (dantrolene) through the nose rather than by mouth may maximize its neuroprotective properties in treating conditions like Alzheimer’s disease, a new study suggests. The study, “Intranasal administration of dantrolene increased brain concentration and duration,” was published in the journal Plos One. Dantrium, produced by Par Sterile Products, is approved by the U.S. Food and Drug…
Caregivers Are Battling on All Fronts to Shield Loved Ones from Pandemic
Caregivers are the first line of defense between their loved ones and, well, everything. Like everyone on the planet, our brains are steeped with thoughts of the coronavirus. It’s our job to stand between our loved ones and the communicable disease, but it’s also our responsibility to keep them from becoming overwrought by all the…
Herzuma, Biosimilar to Herceptin, Available in US for HER2-positive Breast Cancers
Herzuma, a biosimilar to Genentech‘s Herceptin (trastuzumab), is now available in the U.S. for the same indications as the reference therapy, including for the treatment of HER2-positive breast cancers and stomach cancers. The treatment was approved by the U.S. Food and Drug Administration (FDA) in December 2018, the same year it was approved by the European Medicines Agency.…
Harbour BioMed Gets FDA Nod to Start US Trials of 2 Immunotherapies
The U.S. Food and Drug Administration (FDA) has approved Harbour BioMed’s investigational new drug applications to initiate U.S. clinical trials testing two of its immunotherapy candidates — HBM9167 and HBM4003 — in several cancers. HBM9167 and HBM4003 are immune checkpoint inhibitors designed to boost the body’s anti-tumor responses by blocking the proteins that cancer cells use to…
MD Anderson Cancer Center to Acquire Latest in Elekta Radiotherapy Systems
The University of Texas MD Anderson Cancer Center has signed a contract with Elekta to acquire Elekta Infinity linear accelerators and brachytherapy afterloaders, as well as software and services. Elekta, which specializes in tools and systems to treat cancer and brain disorders, claims that its innovations are behind most of the critical technological advances in radiation oncology over the…
GSK Presents Data Showing Combo Therapy Eased Flares in COPD Patients at Risk of CVD
GlaxoSmithKline (GSK) recently presented new data from a pre-specified analysis of the SUMMIT clinical trial, showing that once daily treatment with Breo Ellipta (fluticasone furoate/vilanterol) reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients compared to placebo. The presentation was one of two given at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, California. Breo Ellipta is an inhaled corticosteroid/long-acting…